Drug Trial Radar · NCT04836507
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
91
Planned (sponsor's estimate)
Start
Mar 2, 2021
Primary completion
Aug 15, 2030
Study completion Sep 26, 2030
Sponsor
- Lead sponsor
- Curocell Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.
Conditions
- Relapsed Large B-cell Lymphoma
- Refractory Large B-cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
- High-grade B-cell Lymphoma
- Transformed Follicular Lymphoma (TFL)
- ALL (Acute B-Lymphoblastic Leukemia)
Interventions
CRC01Biological
Cohort A :A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg. Cohort B :A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 1.5 x 10\^6 anti-CD19 CAR T cells/kg.
FludarabineDrug
Administered according to package insert
CyclophosphamideDrug
Administered according to package insert
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Study: Maximum Tolerated Dose (MTD) which will be the Recommended Phase 2 Dose (RP2D)Time frame: 28 days
- Phase 2 Pivotal Study: Cohort A : Overall Response Rate (ORR) Cohort B : Overall Complete Remission Rate (OCR)Time frame: 5 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Seoul, South Korea · Recruiting
The Catholic University of Korea Seoul St. Mary's Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.